Table 5 Clinical manifestations according to age at diagnosis
From: Clinical, genetic and quality-of-life study of a cohort of adult patients with tuberous sclerosis
Age at diagnosis | |||
|---|---|---|---|
Childhood (N = 28) | Adult (N = 26) | p-value | |
Seizures | |||
No | 17.9% (5) | 53.8% (14) | 0.038 |
Yes, controlled, no seizure in 1 year | 60.7% (17) | 30.8% (8) | |
Yes, controlled, seizure in last year | 10.7% (3) | 3.8% (1) | |
Uncontrolled | 10.7% (3) | 11.5% (3) | |
TAND | |||
No | 28.6% (8) | 88.5% (23) | < 0.0001 |
Mild | 39.3% (11) | 7.7% (2) | |
Moderate | 17.9% (5) | 0% (0) | |
Severe | 14.3% (4) | 3.8% (1) | |
Cortical dysplasia | |||
No | 17.9% (5) | 11.5% (3) | 0.514 |
Yes | 82.1% (23) | 88.5% (23) | |
Subependymal nodule | |||
No | 25% (7) | 65.4% (17) | 0.003 |
Yes | 75% (21) | 34.6% (9) | |
Astrocytomas | |||
No | 46.4% (13) | 96.2% (25) | < 0.0001 |
Yes | 53.6% (15) | 3.8% (1) | |
AML | |||
No | 10.7% (3) | 69.2% (18) | < 0.0001 |
Single | 0% (0) | 7.7% (2) | |
Various | 10.7% (3) | 7.7% (2) | |
Multiple > 3 | 78.6% (22) | 15.4% (4) | |
LAM | |||
No | 67.9% (19) | 73.1% (19) | 0.676 |
Mild | 21.4% (6) | 15.4% (4) | |
Moderate | 7.1% (2) | 11.5% (3) | |
Severe | 3.6% (1) | 0% (0) | |
Skin | |||
No | 7.1% (2) | 30.8% (8) | 0.026 |
Yes | 92.9% (26) | 69.2% (18) | |
Rhabdomyoma | |||
No | 57.1% (16) | 84.6% (22) | 0.027 |
Yes | 42.8% (12) | 15.4% (4) | |
Retinal hamartoma | |||
No | 71.4% (20) | 92.3% (24) | 0.048 |
Yes | 28.6% (8) | 7.7% (2) | |
mTOR inhibitors | |||
No | 32.1% (9) | 84.6% (22) | < 0.0001 |
Yes | 67.9% (19) | 15.4% (4) | |